18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用

郑磊 ,  李前伟

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2008,  32 > 1: (23-26)  
引用本文:
shu
Citation:
shu

18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用

  • 400038 重庆, 第三军医大学附属西南医院核医学科

    • 通讯作者: 李前伟, liqw@mail.tmmu.com.cn

  • 中图分类号: R817.4

Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma

  • Department of Nuclear Medicine, Southwest Hospital of Third Military Medical University, Chongqing 400038, China

    • Corresponding author: LI Qian-wei, liqw@mail.tmmu.com.cn

  • CLC number: R817.4

  • 摘要: 肝细胞癌(HCC)的早期诊断是获得临床治愈的关键,准确分期是制定合理治疗方案的基础。尽管18F-氟脱氧葡萄糖(18F-FDG)PET诊断HCC的总体敏感性不高,但其阳性显像与肿瘤分化程度、肝内外转移、门静脉癌栓及血清甲胎蛋白水平等许多因素相关。因此,18F-FDG PET在中、低分化的HCC诊断、分期与再分期、监测治疗反应、评价疗效、判断预后以及鉴别肝脏良性疾病等方面具有独特的价值。
    Abstract: Early diagnosis of hepatocellular carcinoma (HCC)is the key point for clinic healing, and accurate staging is the foundation of rational therapy. Positron emission tomography with 18F-fluorodeoxyglucose(18F-FDG) PET isn't sufficiently sensitive on detecting HCC, hut the positive imaging is related on many factors such as malignant degree, intra/extrahepatic metastases, tumor thromhus in a portal vein, the level of alpha-fetoprotein in blood serum and so on. Thus, 18F-FDG PET has a special value on moderately or poorly differentiated HCC for differential diagnosing, staging and restaging, monitoring responses to treatments, evaluating therapeutic effects, and predicting the prognosis.
  • [1] Lee JD, Yang WI, Park YN, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake[J]. J Nucl Med, 2005, 46(10):1753-1759.
    [2] Yu Kuang, Schomisch SJ, Chandramouli V, et al. Hexokinase and glu-cose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma[J]. Comp Biochem Physiol, C Toxicol Pharmacol, 2006, 143(2):225-231.
    [3] Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET[J]. J Nucl Med, 1995, 36(10):1811-1817.
    [4] 李正平,周杰,张峻,等.18F-FDG PET在原发性肝癌中的诊断作用[J].肝胆外科杂志,2005,13(5):351-354.
    [5] Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, Pglycoprotein expression, and outcome after resection in hepatocellular carcinoma[J]. Clin Cancer Res, 2007, 13(2Pt 1):427-433.
    [6] Yang SH, Suh KS, Lee HW, et al. The role of 18F-FDG-PET imaging for the selection of liver transplavtation candidates from among hepatocellular carcinoma patients[J]. Transplantation, 2006, 82(1 Suppl 2):350.
    [7] Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emissiontomography with fluorine-18-fluorodeoxyglucose in the diagnosis of livertumors[J]. Ann Nucl Med, 2000, 14(2):121-126.
    [8] Jeng LB, Changlai SP, Shen YY, et al. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers[J]. Hepatogastroenterology, 2003, 50(54):2154-2156.
    [9] Kurtaran A, Becherer A, Pfeffel F, et al. 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia(FNH) of the liver[J]. Liver, 2000, 20(6):487-490.
    [10] Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma[J]. J Gastroenterol, 2004, 39(10):961-968.
    [11] Kuker RA, Mesoloras G, Gulec SA. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease[J]. Int Semin Surg Oncol, 2007, 4:17.
    [12] Wudel LJ, Delbeke D, Morris D, et al. The role of[18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma[J]. Am Surg, 2003, 69(2):117-124.
    [13] Lai P, Bomanji JB, Mahmood S, et al. Detection of tumour thrombus by 18F-FDG-PET/CT imaging[J]. Eur J Cancer Prey, 2007, 16(1):90-94.
    [14] Ludwig V, Hopper OW, Martin WH, et al. 18F-Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation; a case report[J]. Am Surg, 2003, 69(7):593-598.
    [15] 赵明,吴沛宏,曾益新,等.18FDG-PET/CT对评价TACE联合RFA治疗原发性肝癌的效果的价值[J].癌症,2005,24(9):1118-1123.
    [16] 谭志斌,赵明,吴沛宏,等.18F-FDG PET/CT在原发性肝癌介入治疗中的价值[J].介入放射学杂志,2005,14(6):588-591.
    [17] Blokhuis TJ,Van Der Schoof MC,Van Den Tol MP, et al. Results of radio frequency ablation of primary and secondary liver tumors:Long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. Scand J Gastroenterol Suppl, 2004, (241):93-97.
    [18] 商健彪,李彦豪,刘方颖,等.18F-FDG PET显像在肝细胞癌介入治疗后残留病灶检出中的应用[J].中华核医学杂志,2004,24(6):325-327.
    [19] Szyszko T, AF Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres:Value of FDG PET versus computed tomography[J]. Nucl Med Commun, 2007, 28(1):15-20.
    [20] Wang XL, Li H, Wang QS, et al. Clinical value of pre-and postoperative 18F-FDG PET/CT in patients undergoing liver transplantatiOn for hepatocellular carcinoma[J]. J South Med Univ, 2006, 26(8):1087-1091.
    [21] 蒋宁一,张弘,王捷,等.25例肝癌术后患者18F-FDG SPECT/CT同机融合显像分析[J].生物医学工程与临床,2004,8(2):100-102.
    [22] Kong YH, Han CJ, Lee SD, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma[J]. Korean J Hepatol, 2004, 10(4):279-287.
  • [1] 杨吉刚 , 李春林 . 18F-氟脱氧葡萄糖PET及PET-CT在食管癌中的. 国际放射医学核医学杂志, 2007, 31(1): 31-33.
    [2] 曹霞 , 谢爱民 , 莫逸 , 彭翔 . 18F-氟脱氧葡萄糖PET-CT在非小细胞肺癌临床分期及经治患者疗效评价中的应用. 国际放射医学核医学杂志, 2008, 32(4): 214-216.
    [3] 李剑明 , 李亚明 . 棕色脂肪组织与18F-氟脱氧葡萄糖PET. 国际放射医学核医学杂志, 2007, 31(4): 205-207,231.
    [4] 赵德善 , 乔振华 . 18F-氟脱氧葡萄糖PET-CT在淋巴瘤中的应用价值. 国际放射医学核医学杂志, 2007, 31(3): 141-144.
    [5] 宋少莉 , 黄钢 . 18F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展. 国际放射医学核医学杂志, 2007, 31(5): 284-288.
    [6] 邢岩 , 赵晋华 . 18F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.
    [7] 叶慧 , 莫逸 , 谢爱民 , 彭翔 . 18F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
    [8] 张悦 , 高硕 . 18F-氟脱氧葡萄糖PET在淋巴瘤中的应用价值. 国际放射医学核医学杂志, 2007, 31(5): 292-295.
    [9] 杨忠毅 , 管樑 . 18F-氟脱氧葡萄糖PET在体检中的应用价值研究. 国际放射医学核医学杂志, 2007, 31(5): 289-291,317.
    [10] 张悦 . 18F-氟脱氧葡萄糖PET和PET-CT在结直肠癌术后复发或转移中的应用价值. 国际放射医学核医学杂志, 2007, 31(1): 34-36.
    [11] 吕慧清 , 张中民 , 吕仲虹 . 18F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1416
  • HTML全文浏览量:  146
  • PDF下载量:  2
出版历程
  • 收稿日期:  2007-06-15

18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用

    通讯作者: 李前伟, liqw@mail.tmmu.com.cn
  • 400038 重庆, 第三军医大学附属西南医院核医学科
  • 收稿日期: 2007-06-15

摘要: 肝细胞癌(HCC)的早期诊断是获得临床治愈的关键,准确分期是制定合理治疗方案的基础。尽管18F-氟脱氧葡萄糖(18F-FDG)PET诊断HCC的总体敏感性不高,但其阳性显像与肿瘤分化程度、肝内外转移、门静脉癌栓及血清甲胎蛋白水平等许多因素相关。因此,18F-FDG PET在中、低分化的HCC诊断、分期与再分期、监测治疗反应、评价疗效、判断预后以及鉴别肝脏良性疾病等方面具有独特的价值。

English Abstract

    全文HTML

参考文献 (22)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net